Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Faron Pharmaceuticals Share News (FARN)
FARN Share
Price
FARN Share
News
FARN Share
Chat
FARN Share
Trades22
FARN
Live RNS
FARN Share
Charts
FARN Level 2
Console
FARN Live
Share Price
FARN Broker
Ratings
FARN Directors
Deals
FARN Financial
Diary
FARN
Fundamentals
FARN Short
Positions
FARN
Media
FARN Company
Research
FARN Company
Timeline
Share Price Information for Faron Pharmaceuticals (FARN)
Last checked at -
Last checked at 
Intraday Faron Pharmaceuticals Share Chart
Faron Pharmaceuticals Notes Study Supporting Clevegen Programme
LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said an article published in the Journal of Immunology has outlined the functional role of the company's Clever-1 treatment, part of its Clevegen cancer immunotherapy antibody programme.
Faron, which floated in London earlier this month, said the data published in the study supported Clever-1 as an immuosuppresive molecule and supports the use of Clevegen as an immunotherapy product.
"We are working hard to advance our Clevegen programme, as announced recently, towards clinical use as a new onco-immunological alternative," said Faron Chief Executive Markku Jalkanen.
Shares in Faron were trading flat at 275.00 pence on Monday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Latest FARN News
- Faron Pharmaceuticals names James O'Brien as CFO
29 Mar 2023 - Faron Pharmaceuticals gets positive feedback from FDA meeting
22 Mar 2023 - UK shareholder meetings calendar - next 7 days
17 Mar 2023 - Faron Pharmaceuticals annual loss widens on higher research costs
3 Mar 2023 - UK earnings, trading statements calendar - next 7 days
24 Feb 2023 - TRADING UPDATES: Diaceutics wins two deals; Faron proposes placing
27 Jan 2023 - IN BRIEF: Faron Pharmaceuticals raises EUR12 million via shares
27 Jan 2023 - AIM WINNERS & LOSERS: Faron Pharmaceuticals raises EUR12 million
27 Jan 2023
Related News
IN BRIEF: Faron Pharmaceuticals fined EUR30,000 by Nasdaq Helsinki
Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Says the Disciplinary Committee of Nasdaq Helsinki Ltd has imposed an EUR30,0...
WINNERS & LOSERS: James Cropper sees earnings up; Block sells stake
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Tuesday.
Faron Pharmaceuticals News
Faron Pharmaceuticals names James O'Brien as CFO
(Sharecast News) - Drug discovery and development company Faron Pharmaceuticals has tapped James O'Brien to take over as its new chief financial offic...
Faron Pharmaceuticals gets positive feedback from FDA meeting
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals said on Wednesday that it had received positive feedback from the US...
Faron Pharmaceuticals annual loss widens on higher research costs
(Alliance News) - Faron Pharmaceuticals Ltd on Friday reported a widened loss in 2022 as it ramped up its research & development efforts.
TRADING UPDATES: Diaceutics wins two deals; Faron proposes placing
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
IN BRIEF: Faron Pharmaceuticals raises EUR12 million via shares
Faron Pharmaceuticals Ltd - Turku, Finland-based biopharmaceutical drug discovery and development company - Raises EUR12.0 million via placing of 3.7 ...
AIM WINNERS & LOSERS: Faron Pharmaceuticals raises EUR12 million
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.
Follow the stocks
